Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT04570865
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT04570865
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT04570865. Allocation not applicable; no masking; primary purpose treatment. Start 2020-12-01 (anticipated); primary completion 2021-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®
- Acronym
- DAPA-MEMS
- Condition
- Heart Failure, Systolic
- Intervention (Drug)
- Dapagliflozin
- Intervention (Device)
- CardioMEMS
- Lead sponsor
- Scripps Health
Record details
- Record id
cardio:ct-nct04570865- Content hash
f6781c6e0dc58f1c61775ff2b0fdc506fa696e2338d55f78dc4595f7df7cac01